IL187138A0 - Compositions and methods for treating conditions related to ephrin signaling with cupredoxins - Google Patents

Compositions and methods for treating conditions related to ephrin signaling with cupredoxins

Info

Publication number
IL187138A0
IL187138A0 IL187138A IL18713807A IL187138A0 IL 187138 A0 IL187138 A0 IL 187138A0 IL 187138 A IL187138 A IL 187138A IL 18713807 A IL18713807 A IL 18713807A IL 187138 A0 IL187138 A0 IL 187138A0
Authority
IL
Israel
Prior art keywords
cupredoxins
compositions
methods
conditions related
treating conditions
Prior art date
Application number
IL187138A
Other languages
English (en)
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of IL187138A0 publication Critical patent/IL187138A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL187138A 2005-05-20 2007-11-04 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins IL187138A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68281205P 2005-05-20 2005-05-20
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US76474906P 2006-02-03 2006-02-03
PCT/US2006/019684 WO2007018671A2 (en) 2005-05-20 2006-05-19 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins

Publications (1)

Publication Number Publication Date
IL187138A0 true IL187138A0 (en) 2008-02-09

Family

ID=37727776

Family Applications (1)

Application Number Title Priority Date Filing Date
IL187138A IL187138A0 (en) 2005-05-20 2007-11-04 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins

Country Status (10)

Country Link
EP (1) EP1888106A4 (ko)
JP (1) JP2008539795A (ko)
KR (1) KR20080040631A (ko)
AU (1) AU2006277009A1 (ko)
BR (1) BRPI0612424A2 (ko)
CA (1) CA2608512A1 (ko)
IL (1) IL187138A0 (ko)
MX (1) MX2007014598A (ko)
NO (1) NO20076391L (ko)
WO (1) WO2007018671A2 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
AU2005327535A1 (en) 2004-10-07 2006-08-24 Ananda Chakrabarty Cupredoxin derived transport agents and methods of use thereof
AU2006284490A1 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins
WO2007012004A2 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
CN101595124A (zh) * 2006-09-14 2009-12-02 伊利诺斯大学理事会 使用铜氧还蛋白预防癌症的组合物及方法
EP2117573A4 (en) * 2007-01-11 2011-02-16 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING EPHRIN SIGNALING WITH CUPREDOXINES AND MUTANTS THEREOF
TWI443109B (zh) 2007-08-30 2014-07-01 Daiichi Sankyo Co Ltd 抗ｅｐｈａ２抗體
KR101102829B1 (ko) * 2008-09-12 2012-01-05 재단법인 제주테크노파크 구멍갈파래 추출물과 그것의 항염증제로서의 용도
CN110090295B (zh) * 2018-01-29 2022-12-23 武汉康理通科技有限公司 Ephrin-B1在制备治疗炎症性肠病的药物中的用途
WO2023205752A2 (en) * 2022-04-22 2023-10-26 University Of Miami Ephrin ligand mimetic peptides for the treatment of neurodegenerative diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2436224A1 (en) * 2001-02-15 2002-10-03 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death

Also Published As

Publication number Publication date
CA2608512A1 (en) 2007-02-15
NO20076391L (no) 2008-02-15
AU2006277009A1 (en) 2007-02-15
JP2008539795A (ja) 2008-11-20
WO2007018671A3 (en) 2007-11-22
EP1888106A2 (en) 2008-02-20
MX2007014598A (es) 2008-02-07
WO2007018671A2 (en) 2007-02-15
BRPI0612424A2 (pt) 2009-01-27
EP1888106A4 (en) 2009-01-14
KR20080040631A (ko) 2008-05-08

Similar Documents

Publication Publication Date Title
IL187138A0 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
AP2885A (en) Methods and compositions for improving plant health
EP1899480A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS
ZA200800187B (en) Methods for increasing the resistance of plants to hypoxic conditions
GB2469243B (en) Improvements in or relating to ablutionary installations
IL184698A0 (en) Composition and method for improving plant health
IL229039A0 (en) Solid preparations and methods for treating insomnia in the middle of the night
EP1895838A4 (en) COMPOSITIONS AND METHODS
PL2137210T3 (pl) Nowy sposób i kompozycje
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
EP2043671A4 (en) METHOD AND COMPOSITIONS FOR TREATING APOPLEXY WITH FEVER
IL191237A0 (en) Compositions and methods for treating thrombocytopenia
IL197602A0 (en) Compositions and methods to prevent cancer with cupredoxins
EP2088865A4 (en) METHODS AND COMPOSITIONS AROUND GUGGULPHOSPHOLIPIDS
GB0617171D0 (en) Novel compositions and methods
ZA200710205B (en) Solid compositions and methods for treating middle-of-the night insomnia
EP2278984A4 (en) COMPOSITIONS AND METHODS FOR ENHANCING FERTILITY
ZA200709939B (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
EP2059122A4 (en) METHODS AND COMPOSITIONS RELATING TO THE EXPRESSION OF APOBEC-I
GB0500224D0 (en) Improvements in or relating to ablutionary installations
GB0501348D0 (en) Compositions and methods
GB0714599D0 (en) Composition and methods relating to photopolymer
EP2117573A4 (en) COMPOSITIONS AND METHODS FOR TREATING EPHRIN SIGNALING WITH CUPREDOXINES AND MUTANTS THEREOF
EP2032146A4 (en) METHOD AND COMPOSITIONS FOR TR4
GB0503412D0 (en) Methods and compositions to treat glaucoma